HeartBeat.bio Funding Round

11/3/2023

Venture Equity

$4,804,000

Seed

The company intends to use the funds to enable the completion of a cardioid drug discovery platform for proprietary and collaborative drug discovery programs in indications such as drug-induced and genetic cardiomyopathies, as well as myocardial infarction and fibrosis.

Private & Independent

Biopharmaceutical

Vienna Biocenter 6 Drive Bohr Gasse 7
Vienna, 1030
AT

Undisclosed

Operator of a drug discovery company intended to focus on the development of a fully human high-throughput three-dimensional screening for heart failure using the world's first self-organizing cardiac organoids. The company generates iPSC-derived, multi-cellular, and lineage-controlled cardiac tissue models from healthy donors or patients that recapitulate the physiology of the human heart, enabling healthcare professionals to radically change the current cardiovascular drug discovery paradigm, leading to higher success rates in clinical trials while reducing the cost and time of compound development.